市場調査レポート - 236763

遺伝子検査の世界市場

Genetic Testing

発行 Global Industry Analysts, Inc.
出版日 ページ情報 英文 343 Pages
価格

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。 PDFのダウンロード・閲覧には Adobe Digital Editions が必要となります。ご購入頂いた場合、同Adobe Digital Editions (ご購入時無償配布)をPCにインストールして頂き、ダウンロードを行ったPC上のみでの閲覧と、1回のプリントアウトが可能となっております。ご不明な点につきましてはお問合せください。

Back to Top
遺伝子検査の世界市場 Genetic Testing
出版日: 2015年05月01日 ページ情報: 英文 343 Pages
概要

当レポートでは、遺伝子検査の世界市場に注目し、2014-2020年の期間を対象に取引価額を製品セグメント (出生前および新生児遺伝子検査、薬理ゲノミクス検査、予測診断) および地域 (米国、カナダ、日本、欧州、アジア太平洋地域、その他) の別に検証・予測するほか、過去7年にわたる市場経緯の分析や大小参入企業86社のプロフィールなど現在の競合環境についての調査情報をまとめています。

第1章 イントロダクション、調査方法、製品の定義

  • 調査の信頼性とレポートの限界
  • 免責事項
  • データの解釈とレポート作成レベル
    • 定量技法と分析
  • 製品の定義と調査範囲
    • 出生前および新生児遺伝子検査薬理遺伝子検査、薬理ゲノミクス検査
    • 予測診断

第2章 エグゼクティブサマリー

  • 世界市場概要
    • 概略基礎知識
    • 世界の10大遺伝子障害
    • 遺伝子検査 - 新時代到来を告げるもの
    • テーラーメイド医療への地歩を固める遺伝子検査
    • 世界人口の膨張がもたらす成長機会拡大
    • 人口老齢化で加速する遺伝子検査市場
    • 医療支出の向上で需要に弾み
    • 遺伝子検査 - 急発展しつつある体外診断薬 (IVD) 市場に不可欠な要素
    • 遺伝子検査 - 分子診断市場の急成長セグメント
    • 遺伝検査の進歩につながったバイオマーカーの発見
    • 米国食品医薬品局承認のがんに対するバイオマーカー一覧
  • セグメント考察
    • 浮上する出生前検査
    • 事象、発現症状、有病率別遺伝子障害一覧
    • 出生前検査 - 妊娠治療の世界を変えるもの
    • 出生前検査 - 基本的概要
    • 利用可能な出生前スクリーニングおよび診断法の症状別一覧
    • 従来の出生前診断技法 - 危険性を伴う仕事
    • 激化する胎児染色体検査 (NIPD) 市場での競争
    • 従来診断法の危険性や不確実性を排除する胎児染色体検査
    • 胎児染色体検査法への異論 - 普及への大きな難関
    • 出生前検査の利点や普及を妨げる倫理問題
    • 利点が潜在的障害を重要度で上回る胎児染色体検査
    • 胎児染色体検査の普及に影響する主なファクター
    • 胎児染色体検査に期待される用途の多様性
    • 予測診断
    • 堅実に拡大する乳がん遺伝子検査市場
    • 多種多様な遺伝学 - 乳がん検査において疑う余地のない第一の分野
    • ルーチン臨床テスト vs. 予測遺伝子検査
    • CDD発性数・有病率の拡大 - 主要成長推進要因
    • 予測診断に不可欠な新型バイオマーカーの発見
    • 未解決の問題が 一対遺伝子病を対象とした遺伝子診断や検査の広範な実施の妨げに
    • 遺伝子カウンセラーの不足 -予測遺伝子試験市場にとっての大きな障害
    • 薬理ゲノミクスの発展が遺伝子検査市場成長への吉兆に
  • 市場動向
    • 外来 (Direct-to-Consumer) 遺伝子検査 - 遺伝子検査市場における主要トレンド
    • 新企業のためのプラットフォームづくり
    • 外来遺伝子検査事業者のためのビジネスモデル
    • 認知を広げる外来遺伝子検査 - その良否
    • 着床前遺伝子診断 (PGD) - 遺伝子検査市場の主要推進材料
    • 全ゲノム解読 - 遺伝子検査への功罪
    • 台頭するアルツハイマー患者向け遺伝子検査の有効性
    • ワーファリン研究目的の遺伝子検査の効用
    • 腫瘍学 - 遺伝子検査の基軸重点分野
    • 遺伝子検査が中枢神経系疾患治療に役立つ可能性も
    • 神経変性疾患 - 遺伝子検査市場の代表的重点分野
    • アルツハイマー病
    • ハンチントン病
    • 遺伝子検査 - 嚢胞性線維症に不可欠なツール
    • 組織適合性検査
    • 次世代シークエンシング - ゲノム解読の巨大な飛躍
    • 急速に支持を得る成人期発症疾患スクリーニングのための小児遺伝子検査
    • 改善を要する世界の遺伝子検査産業に対する安全性規定
    • 直面する課題
    • 遺伝カウンセリング - 高まる機運
    • オンラインによる取り組みに弾み
    • ACOG (The American congress of obstetricians and gynecologists) や ACGM (Advisory Committee on Genetic Modification) の推奨を受けて拡大する嚢胞性線維症検査への需要
    • 倫理問題と適切な規制政策の必要性
    • 肥満に対する遺伝子検査に関する問題点
    • 妊娠期の診断と治療 - 梅毒関連の死亡・死産を減らす有効な方法
  • 分子診断市場 - 考察
    • 急成長カーブを辿る世界の分子診断
    • 自動化で加速する世界市場
    • 分子診断 - 多岐にわたる技術の融合が成したもの
    • 急発展する感染病分子診断市場
    • 人口老齢化、疾患発生 - 成長の基礎的推進要因
    • 分子診断市場に自社の専門領域形成を画す医薬品メーカー
    • 適正な疾患に対する適正な治療の仕立てに向けて
    • サードパーティー機関による限られた医療報酬 - 障害
    • 臨床結果の向上をもたらす疾患特定型の分子診断
    • 分子診断と知的財産権
    • 近い将来の商機
    • 医療トレーニングおよび診療行為の課題
    • 分子診断に着目する企業全般にとっての障害
    • 製品マーケティング - 商業的成功のカギ
    • 分子診断を治療に統合する
    • 分子診断 - 集中化から分散化への転換
    • 分子診断市場の競合環境
    • その他の注目すべき企業と各社のセグメント別競合ポジション
    • アンメットニーズに着目する新規参入企業
  • 製品概要
    • 遺伝子検査についての前置き
    • 遺伝子検査とその利用目的
    • 候補遺伝子とゲノム選別
    • 遺伝子に踏み込むDNAチップ
    • 遺伝子変異の検出に用いられる技法
    • 遺伝子検査の種類
    • 出生前診断
    • がん検査
    • 保因者検出
    • 新生児検診
    • 予測試験
    • 発症前検査
    • 細胞遺伝学検査
    • 遺伝子検査プロセスの段階
    • 制約
    • リスクほか細胞遺伝学検査の制約
    • 遺伝子検査の恩恵を受ける医療機関
    • 薬理遺伝学、薬理ゲノム学
    • 代表的遺伝子検査レビュー
    • 嚢胞性線維症
    • 乳がんおよび卵巣がん (BRCA)
    • アルツハイマー病
    • 大腸がん
    • ヘモクロマトーシス (HH)
    • コーデン症候群
    • ハンチントン病
    • 代表的な検査の費用
    • 遺伝子検査の技法
    • 信号増幅技術
    • 定量リアルタイムPCR解析
    • 非PCR法
    • その他の信号増幅技術
    • DNAプローブ利用製品
  • 製品発売・技術革新
  • 最新産業動向
  • 世界の主要参入企業
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他欧州諸国
  • アジア太平洋地域
  • その他の地域

第4章 競合環境

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

This report analyzes the worldwide markets for Genetic Testing in US$ Million by the following Product Segments: Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 86 companies including many key and niche players such as -

Abbott Laboratories
AutoGenomics, Inc.
BioRad Laboratories
ELITech Group S.P.A
PerkinElmer, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prenatal Diagnosis and Newborn Genetic Testing
    • Pharmacogenetics/Pharmacogenomics
    • Predictive Diagnostics

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

  • A Curtain Raiser
  • Top Ten Genetic Disorders Worldwide
  • Genetic Testing: Heralding a New Era
  • Genetic Testing Paves the Way for Personalized Medicine
    • Table 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medicine (includes corresponding Graph/Chart)
  • Ballooning Global Population Offers Increased Growth Opportunities
    • Table 2: Top 25 Countries Worldwide in Terms of Population: 2007, 2010 & 2015 (As of May'15)
  • Aging Population Drives the Genetic Testing Market
    • Table 3: Global Population Statistics for the 65+ Age Group (2014) (includes corresponding Graph/Chart)
    • Table 4: Elderly Population (60+ Years) as a Percentage of the Total Population (2012 & 2050) (includes corresponding Graph/Chart)
    • Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
    • Table 6: Global Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Drive Demand
    • Table 7: Per-Capita Healthcare Expenditure in Select Regions: 2014 (includes corresponding Graph/Chart)
    • Table 8: Healthcare Spending as a Percentage of GDP by Region: 2014 (includes corresponding Graph/Chart)
  • Genetic Testing - A Critical Part of the Rapidly Developing In-Vitro Diagnostics (IVD) Market
    • Table 9: Global In Vitro Diagnostics (IVD) Market by Geographic Region (2014): Percentage Share Breakdown of Revenues for the United States, Europe, and Rest of World (includes corresponding Graph/Chart)
    • Table 10: Global In-Vitro Diagnostics Market by Sector (2014): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, and Decentralized & Patient Self-Testing (includes corresponding Graph/Chart)
    • Table 11: Global In-Vitro Diagnostics Market by Segment (2014): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
    • Table 12: Global In Vitro Diagnostics Market by Leading Player (2014): Percentage Share Breakdown of Revenues for Abbott, Biomerieux, Danaher, J&J, Roche, Siemens and Others (includes corresponding Graph/Chart)
  • Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
    • Table 13: Global Molecular Diagnostics Market (2014): Percentage Breakdown of Market Revenues of Infectious Disease Testing, Genomics, and Blood Donor Screening (includes corresponding Graph/Chart)
  • Biomarker Discovery Leads to Advanced Genetic Testing
  • List of US-FDA Approved Biomarkers for Cancer

2. SEGMENTAL REVIEW

  • Prenatal Testing Market to Rise
  • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
  • Prenatal Testing - Changing the World of Pregnancy Care
  • Prenatal Testing - A Rudimentary Overview
  • List of Available Prenatal Screening and Diagnostic Tests by Indication
  • Conventional Pre-Natal Diagnostic Techniques - A Risky Affair
    • Other Negativities of Existing Invasive Techniques
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
  • Competition Intensifies in the NIPD Market
    • Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
  • NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures
  • Opposition to NIPD Technique - A Significant Hurdle to Adoption
  • Ethical Issues Bog Down Benefits and Proliferation of Prenatal Testing
  • Benefits Outweigh Snags in NIPD Tests
  • Major Factors Influencing Penetration of NIPD Tests
    • Table 14: Price Comparison of Existing Tests and Screening Procedures for Down's Syndrome
  • Diversity in NIPD Usage on the Cards
    • Expanded Newborn Screening
  • Predictive Diagnostics
  • Breast Cancer Gene Testing Market to Expand Strongly
  • Myriad Genetics - The Unquestioned Leader in Breast Cancer Testing
  • Routine Clinical Testing Vs. Predictive Genetic Testing
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
  • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
  • Unresolved Issues Hamper Widespread Implementation of Genetic Diagnosis and Testing for Monogenetic Disease
  • Dearth of Genetic Counselors - A Major Hurdle for the Predictive Genetic Testing
  • Pharmacogenomics Development Augurs Growth of Genetic Testing Market

3. MARKET TRENDS

  • Direct-to-Consumer Genetic Testing - A Key Trend in the Genetic Testing Market
  • Creating a Platform for New Companies
  • Business Models for DTC Genetic Testing Firms
  • Growing Prominence of DTC Genetic Testing: A Boon or a Curse?
  • Pre-implantation Genetic Diagnosis (PGD) - A Major Driver for the Genetic Testing Market
  • Whole Genome Sequencing - Boon or Bane to Genetic Testing?
  • Validity of Emerging Genetic Tests for Alzheimer's
  • Utility of Genetic Testing for Warfarin Study
  • Oncology - A Key Focus Area for Genetic Testing
    • Table 15: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 16: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
    • Table 17: Cancer Incidence in Developed Nations By Site: 2012 (includes corresponding Graph/Chart)
    • Table 18: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal, and Liver Cancers (includes corresponding Graph/Chart)
    • Table 19: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus, and Liver Cancers (includes corresponding Graph/Chart)
    • Table 20: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
  • Genetic Testing May Aid CNS Disease Therapeutics
  • Neurodegenerative Diseases - Major Focus Area for Genetic Testing
  • Alzheimer's Disease
  • Huntington's Disease
  • Genetic Testing - An Indispensible Tool for Cystic Fibrosis
    • Table 21: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
  • Histocompatibility Testing
    • Table 22: Global HLA Testing Market (2012-2016E): Revenue Estimates for 2012, 2013, 2014, 2015, and 2016 (includes corresponding Graph/Chart)
  • Next-Generation Sequencing - A Giant Leap in Genome Sequencing
  • Pediatric Genetic Testing for Screening Adult Onset Disorders Fast Gaining Acceptance
  • Better Regulatory Safeguards Required for Global Genetic Testing Industry
  • Challenges Faced
  • Genetic Counseling: Gaining Momentum
  • Online Approach Gains Momentum
  • Recommendations of ACOG and ACGM Augments Demand for Cystic Fibrosis Testing
  • Ethical Issues & Need for Appropriate Regulating Policies
  • Issues Related to Genetic Tests for Obesity
  • Diagnosis and Treatment during Pregnancy - An Effective Way of Alleviating Syphilis Related Deaths and Stillbirths

4. MOLECULAR DIAGNOSTICS MARKET - AN INSIGHT

  • Global Molecular Diagnostics on a High Growth Curve
  • Automation Driving Global Market
  • Molecular Diagnostics: Marking the Convergence of Numerous Technologies
  • MDx Market for Infectious Diseases Zooming Ahead
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostics Market
  • Towards Tailoring the Right Treatment for the Right Disease
  • Limited Reimbursements by Third Party Payers - A Stumbling Block
  • Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes
  • Molecular Diagnostics and Intellectual Property
  • Business Opportunities in the Offing
  • Medical Training and Practice Challenges
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Product Marketing - Key to Commercial Success
  • Integration of Molecular Diagnostics into Therapeutics
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Competitive Landscape of the Molecular Diagnostics Market
    • Table 23: Leading Players in the Global Molecular Diagnostics Market (2014): Percentage Share Breakdown by Value Sales for Abbott, Becton, Dickinson & Company, bioMerieux, Cepheid, Hologic/Gen-Probe, Novartis, Qiagen, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
  • Other Noteworthy Companies and their Competitive Position by Segment
  • New Entrants Eye Unmet Needs

5. PRODUCT OVERVIEW

  • Preface to Genetic Testing
  • Genetic Testing and its Applications
  • Gene Candidate and Genome Screen
  • 'DNA Chip' to Chip into Genetic Field
  • Techniques Used to Identify Changes in Genes
  • Types of Genetic Testing
  • Prenatal Diagnosis
  • Cancer Testing
  • Carrier Identification
  • Newborn Screening
  • Predictive Testing
  • Pre-Symptomatic Testing
  • Cytogenetic Tests
  • Steps in Genetic Testing Process
  • Limitations
  • Risks and Other Limitations of Genetic Testing
  • Medical Institutions to Reap the Benefit of Genetic Testing
  • Pharmacogenetics/Pharmacogenomics
  • Review of Select Genetic Tests
  • Cystic Fibrosis
  • Breast and Ovarian Cancer (BRCA)
  • Alzheimer's disease
  • Colorectal Cancer
  • Haemochromatosis (HH)
  • Cowden Syndrome
  • Huntington's disease (HD)
  • Costs of Select Tests
    • Table 24: Costs of Select Genetic Tests
  • Genetic Testing Techniques
  • Signal Amplification Technologies
    • PCR - New Developments
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
  • Applications of Quantitative Real-Time PCR Analysis
    • Viral Detection and Viral-Load Monitoring
    • Sensitive Detection of Infectious Disease Agents
    • Predisposition Testing
  • Non-PCR Methods
  • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
    • RNA Diagnostics

6. PRODUCT LAUNCHES/INNOVATIONS

  • PerkinElmer Launches Genetic Screening Processor® Instruments in China
  • Mayo Clinic Launches Eight NGS Panels for Cardiac Disorders
  • Sequenom Laboratories and Recombine Launch HerediT® UNIVERSAL Test
  • Multipicom NV Launches ADH MASTR™ v2 assay
  • 23andMe Launches Drug Development Unit
  • Quest Diagnostics Launches Neurome™ Exome Sequencing Service
  • Roche Launches cobas 6800/8800 Systems
  • Agena Biosciences Launches MassARRAY 24-Well System
  • FDA Grants Marketing Approval to 23andMe's DTC Bloom Syndrome Carrier Genetic Test
  • Transgenomic to Launch ICE COLD-PCR™ Technology
  • Rosetta Launches Sequencing-based Oncology Tests by Admera Health
  • MedGenome Labs Launches Panorama Prenatal Test
  • Ambry Genetics Launches CVD Genetic Testing Panels
  • Exceltox Launches Pharmacogenomic Testing
  • PerkinElmer Launches SCID Screening Test in North America
  • Quest Diagnostics Introduces BRCAvantage Plus™
  • Genetic Technologies Launches BREVAGenplus Test
  • Sophia Genetics Receives CE-IVD Certification for Genetic Testing
  • Response Genetics Launches Immuno- Oncology Assay
  • DeNA Life Science Launches Mycode Genetic Testing Service
  • Pathway Genomics Launches BRCATrue™ Test
  • Courtagen Launches Genetic Sequencing Tests for Neurodevelopmental Disorders
  • Myriad Genetics Launches EndoPredict® Breast Cancer Test
  • Assurex Health Expands GeneSight® Pharmacogenomic Testing Platform
  • Illumina to Launch VeriSeq Embryo Screening Tool
  • GENEWIZ Launches PGxOne™ Pharmacogenomic Test
  • Ambry Genetics Launches ExomeNext™ and ExomeNext-Rapid™ Genetic Tests
  • Pathway Genomics Launches Genetic Test to Detect Risk of Colorectal Cancer
  • Mount Sinai Laboratory Develops Accurate Genetic Test for SMA
  • Sequenom Launches Non-Invasive Prenatal Test by Laboratoire Cerba
  • CSL Behring Launches Antitrypsin Deficiency Screening Test
  • Interleukin Genetics Launches PerioPredict™
  • US Genomic Health Reports Positive Data from Oncotype DX Prostate Cancer Study
  • Assurex Health Launches GeneSight Test to Predict Folic Acid Conversion and Treat Depression
  • Verifi ® Prenatal Test Available Through California Prenatal Screening Program
  • Children's Mercy Launches TaGSCAN Test
  • General Genetics and Estrogen Gene Test Launch EstroGene™ Test
  • Genetic Analysis Launches GA-map™ Test
  • Myriad Genetics Launches myRisk™ Hereditary Cancer Test
  • GeneDx Launches Genetic Tests for Cancer
  • ArcticDx Launches Vita Risk Pharmacogenetic Test for AMD Patients
  • Quest Diagnostics Launches CYP450 Biomarker- based Diagnostic Test
  • Blueprint Genetics Launches Gene Sequencing Tests
  • Bioiberica Farma Launches Genetic Test for Osteoarthritis
  • Illumina, The Wellcome Trust Centre and the Institute of Cancer Research Roll out Genetic Test
  • Aviir to Launch Genetic Testing for Inherited Cardiovascular Disease
  • Oxford University Hospitals Launches 46-gene Sequencing Test for Cancer

7. RECENT INDUSTRY ACTIVITY

  • ESPERITE Acquires InKaryo
  • Transgenomic Signs Agreement with Exiqon A/S
  • Quest Diagnostics and Myriad Genetics End BRCA Gene Patent Litigation
  • Roche to Acquire Majority Share of Foundation Medicine
  • Roche Acquires Ariosa Diagnostics
  • GSK Collaborates with GE on Oncology Genetic Testing
  • Cancer Genetics to Acquire Gentris Corporation
  • Natera Partners with Mount Sinai Genetic Testing Laboratory
  • Transgenomic to Sell SURVEYOR Nuclease Technology to Integrated DNA Technogies
  • Transgenomic Collaborates with Raptor Pharmaceuticals for Genetic Testing Services
  • AutoGenomic Signs Agreement with Genomas
  • Cancer Genetics Acquires BioServe Biotechnologies
  • PerkinElmer to Close Its Signature Genomics Testing Business
  • LifeLabs Medical Laboratory Services Buys out Centogene's Canadian Business
  • CytoScan Dx Assay by Affymetrix Receives FDA Approval
  • NextGxDx Enters Agreement with PreventionGenetics
  • Neogen Acquires Scidera Genomics
  • Sequenom and CombiMatrix Enter Marketing Agreement for Chromosomal Microarray Analysis
  • Illumina Acquires Verinata Health

8. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • AutoGenomics, Inc. (US)
  • BioRad Laboratories (US)
  • ELITech Group S.P.A. (France)
  • PerkinElmer, Inc. (US)
  • Quest Diagnostics, Inc. (US)
  • Roche Diagnostics Corp. (Switzerland)
  • Roche Molecular Diagnostics, Inc. (US)
  • Thermo Fisher Scientific (US)
  • Transgenomic, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 25: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 27: World 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • The US: Leading Market for Genetic Testing Globally
    • Demographic Changes Offer Growth Opportunities
    • Table 28: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Burgeoning Potential for Genetic Testing
    • Predictive Screening: Another Growth Area
    • An important Market for Personalized Medicine
    • Epidemic Proportion of Cancer in the US - Driver for Cancer Genetic Testing
    • Table 29: US Cancer Incidence by Gender (2014): No. of Reported New Cases for Men and Women (includes corresponding Graph/Chart)
    • Table 30: US Incidence of Common Cancers (2014): Number of New Cases Reported by Affected Site (includes corresponding Graph/Chart)
    • Newborn Testing Gains Ground
      • Success Stories
    • Favorable Reimbursement Policies
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Table 31: CF Carrier Screening: Percentage Breakdown of Population by Coverage Policy: 2012 (includes corresponding Graph/Chart)
    • Table 32: CF Diagnostic Testing: Percentage Breakdown of Population by Coverage Policy: 2012 (includes corresponding Graph/Chart)
    • Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis Numbers
    • Table 33: US Annual Pregnancies by Age Group/Risk Profile: 2010 (includes corresponding Graph/Chart)
    • Tough Market Prospects for Sex Determination Tests
      • Sequenom Bets Big on MaterniT21
    • IP Landscape of NIPD Tests
      • US Patents of cff DNA-based NIPD Tests
    • Direct-to-Consumer Testing - A Growing Market
      • DTC Genetic Tests Provide POCT for Patients in Hospice Care
    • Regulatory Environment
      • Genetic Information Nondiscrimination Act Boosts Genetic Testing
      • NIH Launches Public Database
      • Stricter Regulations for DTC Genetic Testing
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 34: The US Recent Past, Current & Future Analysis for Genetic Testing by Segment - Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 35: The US Historic Review for Genetic Testing by Segment - Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 36: The US 14-Year Perspective for Genetic Testing by Segment - Percentage Breakdown of Dollar Sales for Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Regulatory Scenario
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Table 37: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)
    • Table 38: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)
    • Table 39: New Cancer Cases in Canada by Age Group and Gender: 2012 (includes corresponding Graph/Chart)
    • Product Launch
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 40: Canadian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 41: Canadian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Demographics Drive Market Growth
    • Table 42: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • DTC Genetic Testing Regulatory Scenario
    • Product Launch
  • B. Market Analytics
    • Table 43: Japanese Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 44: Japanese Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Debt Crisis in Europe Affects Healthcare Industry
    • European Healthcare System: In a State of Transition
    • An Insight into Molecular Diagnostics Markets in Europe
    • Cancer Trends
    • Table 45: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • Aging Population to Drive Demand for Genetic Testing
    • Table 46: Population Breakup by Age Group for Select European Countries: 2013 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Legislations/Regulatory Policies in Select European Countries
      • Legislations Governing Genetic Testing in Select European Countries
  • B. Market Analytics
    • Table 47: European Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 48: European Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 49: European 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Regulatory Environment in France
    • Product Launch
    • Elitech Group S.P.A. - A Key Player
  • B. Market Analytics
    • Table 50: French Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 51: French Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Parliamentary Regulations
  • B. Market Analytics
    • Table 52: German Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 53: German Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 54: Italian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 55: Italian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Regulatory Scenario
      • Non-consensual Analysis of DNA Made Illegal
      • Principles for DTC Genetic Testing Laid out by HGC
    • Product Launches
  • B. Market Analytics
    • Table 56: The UK Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 57: The UK Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Product Launches
    • Strategic Corporate Developments
    • Roche Diagnostics Corp. - A Key Player (Switzerland)
  • B. Market Analytics
    • Table 58: Rest of European Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 59: Rest of European Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • Select Regional Markets
      • China
      • China's FDA Curbs Prenatal Testing
    • Table 60: China - The Most Populous Country Worldwide (July 2013): Total Population (in Millions) by Age Group 0-14 Years, 15-44 Years, 45-64 Years, and 65+ Years for China Vis-a-Vis Other Countries (includes corresponding Graph/Chart)
    • Table 61: China - The Most Populous Country Worldwide (July 2013): Percentage Population by Age Group 0-14 Years, 15-44 Years, 45-64 Years, and 65+ Years for China Vis-a-Vis Other Countries (includes corresponding Graph/Chart)
      • Diagnostics Market in India
      • Australia and New Zealand
      • Approval of Experiments on Human Embryos in New Zealand
      • Singapore Sets Guidelines for Genetic Research and Testing
    • Product Launches
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 63: Asia-Pacific Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 64: Rest of World Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 65: Rest of World Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top